Clinical Trials

Find a Clinical Trial

Enrolling Trials

21-30  of  151
►
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
Manalang, Michelle
Germ Cell Tumors
Child
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
Welter, Stacy L
(715) 221-6492
►
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Manalang, Michelle
Lymph Gland
Child
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Manalang, Michelle
Rhabdomyosarcoma/Soft Tissue Sarcoma
Child
This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and cyclophosphamide (VAC) followed by vinorelbine and cyclophosphamide versus VAC followed by vinorelbine and cyclophosphamide for the treatment of high risk rhabdomyosarcoma. Chemotherapy drugs, such as vinorelbine, vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vinorelbine and VAC may kill more tumor cells. Adding maintenance therapy (vinorelbine and cyclophosphamide) after VAC therapy, with or without vinorelbine, may help get rid of the cancer and/or lower the chance that the cancer comes back.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Lee, David
Stomach, Intestine, Gut - Rectum
Adult
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
Craig, Chani L
(715) 358-1838
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Fagbemi, Seth O
Stomach, Intestine, Gut - Pancreas
Adult
This study aims to obtain much needed data to guide oncologists as to the optimal management of patients over the age of 70 with ECOG PS 0-2 and newly diagnosed mPCA.
Tesmer, Brooke
(715) 221-7330
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Fagbemi, Seth O
Stomach, Intestine, Gut - Rectum
Adult
This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab) works for the treatment of patients with colorectal cancer that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic). Regorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab or panitumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this research study is to compare the effects, good and/or bad, of taking regorafenib follow by cetuximab or panitumumab, to those that receive cetuximab or panitumumab before regorafenib.
Adam, Iddrisu
(715) 389-4041
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
►
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
Husak, Michael
Stomach, Intestine, Gut - Rare (Gist, Neuroendocrine, Carcinoid, Anal Canal)
Adult
This phase III trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab together with carboplatin and paclitaxel may help doctors find out if the treatment is better or the same as the usual approach.
Wilson, Anna E
(715) 858-6860
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib for Patients with Advanced malignancies Harboring MEK or Atypical BRAF Alterations
Onitilo, Adedayo A
Mutations - Rare
Adult
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.
Hurley, Alexa A
(715) 393-1019
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A021602, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
Delmastro, Dean A
Stomach, Intestine, Gut - Lung
Adult
This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Wilson, Anna E
(715) 858-6860
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
►
A022001-Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Gokalp Yasar, Demet
Stomach, Intestine, Gut - Pancreas
Adult
This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. The purpose of this study is to find out whether capecitabine and temozolomide or lutetium Lu 177 dotatate may kill more tumor cells in patients with advanced pancreatic neuroendocrine tumors.
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494